ÀÌÈ«±â ¸íÀÇ

35³âÀ» Á־߷ΠȯÀÚ¿Í ÇÔ²²ÇÑ Ç÷¾×¾Ï Ä¡·á Àü¹®°¡

ÀÌÈ«±â ¸íÀÇ

  • ¼Ò ¼Ó
    °Ç±¹´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°ú
  • Àü¹®ºÐ¾ß
    ¹éÇ÷º´, ¸²ÇÁÁ¾, Á¶Ç÷¸ð¼¼Æ÷À̽Ä

ÁÖ¿ä Áø·á ºÐ¾ß´Â ¹éÇ÷º´, ¸²ÇÁÁ¾, Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀÌ´Ù. °Ç±¹´ëÇб³ Àǰú´ëÇаú º´¿ø¿¡ ±³¼ö·Î ÀçÁ÷Çϸ鼭 º´¿øÀå, ÀÇ·á¿øÀå, Àǹ«ºÎÃÑÀåÀ» ¿ªÀÓÇß´Ù.
´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ÀÌ»çÀåÀ» ¿ªÀÓÇß´Ù. °Ç°­º¸Çè½É»çÆò°¡¿ø ºñ»ó±Ù½É»çÀ§¿øÀ¸·Î 15³â µ¿¾È °øÇåÇÏ¿´°í, Çѱ¹Á¶Ç÷¸ð¼¼Æ÷ÀºÇàÇùȸ¿Í Çѱ¹Ç÷¾×¾ÏÇùȸ ÀÌ»ç·Î¼­ 20³â °¡±îÀÌ »çȸ°øÇåÀ» ÇÏ¿´´Ù. 2025³â ÇöÀç °Ç±¹´ëÇб³ ¸í¿¹±³¼öÀÌÀÚ °Ç±¹´ëÇб³º´¿ø ÀÚ¹®±³¼ö·Î Áø·áÇϰí ÀÖÀ¸¸ç, 2024³â 3¿ùºÎÅÍ Çѱ¹Á¶Ç÷¸ð¼¼Æ÷ÀºÇàÇùȸ ȸÀåÁ÷À» ¸Ã°í ÀÖ´Ù. 2017³â Á¦ 20ȸ ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ Çмú»ó ´ë»óÀ» ¼ö»óÇß´Ù. 2018³â °Ç°­º¸ÇèºÐÀïÁ¶Á¤À§¿øÈ¸ À§¿øÀ¸·Î Ȱµ¿Çϸ鼭 °Ç°­º¸Çè Á¦µµ °³¼±¿¡ ±â¿©ÇÑ °øÀ» ÀÎÁ¤¹Þ¾Æ º¸°Çº¹ÁöºÎÀå°ü ǥâÀåÀ» ¼ö»óÇß´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¿¬¼¼´ë ÀÇ´ë Çлç
  • ¿¬¼¼´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • »ï¼º¼­¿ïº´¿ø Ç÷¾×Á¾¾ç³»°ú ±³¼ö
  • °Ç±¹´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°ú ±³¼ö
  • °Ç±¹´ëº´¿ø º´¿øÀå ¹× ÀÇ·á¿øÀå
  • °Ç±¹´ëÇб³ Àǹ«ºÎÃÑÀå
  • ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ÀÌ»çÀå
  • °Ç°­º¸Çè½É»çÆò°¡¿ø ºñ»ó±Ù½É»çÀ§¿ø
  • ½ÄǰÀǾàǰ¾ÈÀüû Áß¾Ó¾à»ç½ÉÀÇÀ§¿øÈ¸ Àü¹®°¡
  • °Ç°­º¸ÇèºÐÀïÁ¶Á¤À§¿øÈ¸ À§¿ø
  • Çѱ¹Á¶Ç÷¸ð¼¼Æ÷ÀºÇàÇùȸ ȸÀå
  • Çѱ¹Ç÷¾×¾ÏÇùȸ ºÎȸÀå(¿ªÀÓ)

¼ö»ó³»¿ª

Awards List
  • ±¹¹«ÃѸ® ǥâÀå (2021)
  • º¸°Çº¹ÁöºÎÀå°ü ǥâÀå (2018)
  • ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ Çмú»ó (2017)
  • Marquis Who' s Who in the World (2007)
  • Marquis Who' s Who in Science and Engineering (2007)
  • Marquis Who' s Who in Medicine and Healthcare (2006)
  • ´ëÇѳ»°úÇÐȸ Çмú»ó (2005)

ÇÐȸȰµ¿

Academic activities
  • 1996 ~ ÇöÀç´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ Á¤È¸¿ø
  • 1996 ~ ÇöÀç´ëÇÑÇ÷¾×ÇÐȸ Á¤È¸¿ø
  • 1996 ~ ÇöÀç´ëÇѾÏÇÐȸ
  • 1996 ~ ÇöÀç´ëÇѳ»°úÇÐȸ Á¤È¸¿ø
  • 1996 ~ ÇöÀçThe American Society of Hematology member
Ç÷¾×ÇÐ
´ëÇ¥¼­Àû

Ç÷¾×ÇÐ

  • ÀúÀÚ(±Û)´ëÇÑÇ÷¾×ÇÐȸ °øÀú
  • ÃâÆÇ»çE*PUBLIC
  • ¹ßÇàÀÏ2006³â 05¿ù 25ÀÏ
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 1°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Haematologica
Á¦ ¸ñ Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Haematologica
Á¦ ¸ñ FDG PET/CT maximum tumor dissemination to predict recurrence in patients with diffuse large B-cell lymphoma
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Nucl Med Mol Imaging
Á¦ ¸ñ Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Korean J Intern Med
Á¦ ¸ñ Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party.
¹ßÇ¥³âµµ 2019 ¹ßÇ¥Áö Ann Hematol
Á¦ ¸ñ Oral mucormycosis in patients with haematologic malignancies in a bone marrow transplant unit
¹ßÇ¥³âµµ 2017 ¹ßÇ¥Áö Mycoses
Á¦ ¸ñ Predictors of general discomfort, limitations in activities of daily living and intention of a second donation in unrelated hematopoietic stem cell donation
¹ßÇ¥³âµµ 2017 ¹ßÇ¥Áö Bone Marrow Transplant

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

ÁÖ¿ä °ü½É/Àü¹® ºÐ¾ß´Â Ç÷¾×¾Ï(¹éÇ÷º´, ¸²ÇÁÁ¾) Ä¡·áÀ̸ç, À̸¦ À§Çؼ­ Ç×¾ÏÈ­Çпä¹ý°ú ¼¼Æ÷Ä¡·á¹ýÀÇ Àû¿ë°ú ¹ßÀü¿¡ Áö³­ 35³â µ¿¾È Àü³äÇϰí ÀÖ´Ù. ±¹Á¦Àû Àü¹®ÇмúÁö¿¡ ¾à 150ÆíÀÇ ³í¹®À» ¹ßÇ¥Çß´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

Àǻ簡 ȯÀÚ Áø·á¿¡ À־ °®Ãß¾î¾ß ÇÒ ´ö¸ñÀº Áø½ÇÇϰí ÂüµÈ Àμº°ú »çȸÀû °øÇå ¸øÁö ¾Ê°Ô Áß¿äÇÑ °ÍÀÌ º¸´Ù ³ªÀº Áúº´ Ä¡·á¸¦ À§Çؼ­ Ç×»ó ²÷ÀÓ¾øÀÌ Àü¹®Áö½ÄÀ» ÇÔ¾çÇÏ°í ½ÀµæÇÏ´Â °ÍÀÌ´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

ÃÖ¼±ÀÇ Áúº´ Ä¡·á´Â ȯÀÚ, ÀÇ·áÁø, º¸È£ÀÚ°¡ ÇÑÆÀÀÌ µÇ¾î ¼­·ÎÀÇ ½Å·Ú ¼Ó¿¡¼­, Ä¡·á ¸ñÇ¥ ´Þ¼ºÀ» À§Çؼ­ ²ÙÁØÈ÷ ³ë·ÂÇÒ ¶§ ÀÌ·ç¾îÁú ¼ö ÀÖ´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°Ç±¹´ëÇб³º´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-1533
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°Ç±¹´ëÇб³º´¿øÀº »óÇã À¯¼®Ã¢ ¼±»ý²²¼­ ÀÏÁ¦ °­Á¡±âÀÎ 1931³â ¹ÎÁ·ÁöµµÀÚµé°ú ¶æÀ» ¸ð¾Æ ±¸·áÁ¦¹Î(Ï­Öûð­ÚÅ)°ú Àμúº¸±¹(ìÒâúÜÃÏÐ)ÀÇ Å« ¶æÀ» ´ã¾Æ ¼³¸³ÇÑ ¡®»çȸ¿µ Á߾ӽǺñÁø·á¿ø¡¯¿¡ »Ñ¸®¸¦ µÎ°í ÀÖ´Ù. 2002³â °Ç±¹´ëÇб³ ¼­¿ïÄ·ÆÛ½º ³²´Ü¿¡ º´¿ø °Ç¹°À» »õ·Î Áþ±â ½ÃÀÛÇØ 2005³â 8¿ù »õ·Ó°Ô žÀ¸¸ç ÁöÇÏ4Ãþ, Áö»ó 13Ãþ ¿¬¸éÀû 2¸¸ 6300¿©ÆòÀÇ »õ °Ç±¹´ëº´¿øÀº 33°³ÀÇ Áø·á°ú¿Í 784°³ÀÇ º´»ó, 9°³ÀÇ ÁßÁ¡¼¾ÅÍ¿Í 14°³ÀÇ Áø·á¼¾ÅÍ, ÇコÄɾÅ͸¦ °®Ãß°í 430¿©¸íÀÇ ÀÇ·áÁøÀÌ Áø·á¸¦ Çϰí ÀÖ´Ù. 2009³â °©»ó¼±¾Ï¼¾ÅÍ, ´ëÀå¾Ï¼¾ÅÍ, À¯¹æ¾Ï¼¾ÅÍ µî ¾Ï¼¾Å͸¦ °³¼³Çϰí, 2017³â 11¿ù¿¡´Â ÃÖ½ÅÇü ·Îº¿ ¸ðµ¨ÀÎ 4¼¼´ë ´ÙºóÄ¡Xi¸¦ µµÀÔ, ·Îº¿¼ö¼ú ¼¾ÅÍ °¡µ¿À» ½ÃÀÛÇß´Ù. °Ç±¹´ëº´¿øÀº ´ëÀå¾Ï, À¯¹æ¾Ï, Æó¾Ï, À§¾Ï, Ç÷¾×Åõ¼®, ¸¸¼ºÆó¼â¼ºÆóÁúȯ µî ÁßÁõÁúȯ ºÐ¾ß Æò°¡¿¡¼­ 1µî±ÞÀ» ±â·ÏÇϰí ÀÖÀ¸¸ç, °ñµçŸÀÓÀÌ Áß¿äÇÑ ½ÉÇ÷°üÁúȯ°ú ³úÇ÷°üÁúȯÀÇ ½Å¼ÓÁø·á½Ã½ºÅÛÀ» ¿î¿µÇÏ¸ç ±Þ¼º±â ³úÁ¹Áß ¹× °ü»óµ¿¸Æ¿ìȸ¼ú Æò°¡¿¡¼­µµ 1µî±ÞÀ» À̾°í ÀÖ´Ù. Áö³­ 2023³â¿¡´Â ÁßÁõÁúȯ Ä¡·á ¿ª·® °­È­¸¦ À§ÇØ ÁßȯÀÚ½Ç ¹× ¼ö¼ú½Ç Áõ¼³, ·Îº¿¼ö¼ú±â±â Ãß°¡ ¹× CTµî ½ÅÇüÀÇ·áÀåºñ µîÀ» µµÀÔÇß´Ù. À̾î 2024³â¿¡´Â ȯÀÚµéÀÇ ÄèÀûÇÑ È¯°æÀ» À§ÇØ º´µ¿ ȯ°æÀ» °³¼±Çϰí, 2025³â¿¡´Â ¿Ü·¡¼¾ÅÍ ÁõÃàÀ» ¾ÕµÎ°í ÀÖ´Ù.

°Ç±¹´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã ±¤Áø±¸ ´Éµ¿·Î 120-1(È­¾çµ¿) °Ç±¹´ëÇб³º´¿ø

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä